Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Cytomegalovirus Infection

  Free Subscription

Articles published in Transplant Proc

Retrieve available abstracts of 55 articles:
HTML format

Single Articles

    March 2021
  1. PEARSTON AP, Ingemi AI, Ripley K, Wilson TJ, et al
    Successful Treatment of UL97 Mutation Ganciclovir-Resistant Cytomegalovirus Viremia in a Renal Transplant Recipient With Letermovir and Adjunct Hyperimmune Cytomegalovirus Immunoglobulin: A Case Report.
    Transplant Proc. 2021 Mar 11. pii: S0041-1345(21)00112.
    PubMed     Abstract available

    September 2020
  2. HEENEY S, Szempruch KR, Lee RM, Mintz A, et al
    The Effect of Tacrolimus Trough Variability on Kidney Transplant Outcomes.
    Transplant Proc. 2020 Sep 4. pii: S0041-1345(20)32670.
    PubMed     Abstract available

    July 2020
  3. KESKINOGLU A, Bulut IK, Taner S, Turkes AZ, et al
    Cytomegalovirus Experience in Pediatric Kidney Transplantation in 26 Years' Time.
    Transplant Proc. 2020 Jul 6. pii: S0041-1345(19)31363.
    PubMed     Abstract available

  4. MINZ RW, Kumar M, Kanwar DB, Sharma A, et al
    Cytomegalovirus Infection in Postrenal Transplant Recipients: 18 Years' Experience From a Tertiary Referral Center.
    Transplant Proc. 2020 Jul 2. pii: S0041-1345(19)31662.
    PubMed     Abstract available

    June 2020
  5. UENO T, Kodama T, Noguchi Y, Deguchi K, et al
    One Year of Preemptive Valganciclovir Administration in Children After Liver Transplantation.
    Transplant Proc. 2020 Jun 19. pii: S0041-1345(19)31851.
    PubMed     Abstract available

  6. ANGELICA AYRES RDC, Fonseca-Neto OCLD, Aquino RCA, Ribeiro KB, et al
    Use of Liver Grafts From Deceased Organ Donors With Infectious Diseases.
    Transplant Proc. 2020;52:1231-1235.
    PubMed     Abstract available

    May 2020
  7. ZMONARSKI SC, Banasik M, Golebiowski T, Letachowicz K, et al
    Toll-Like 4 Receptor Expression on Peripheral Blood Mononuclear Cells in Renal Transplant Recipients Can Help to Indicate the Risk of Graft Deterioration in Patients Who Experienced an Episode of Symptomatic Cytomegalovirus Infection.
    Transplant Proc. 2020 May 19. pii: S0041-1345(20)30146.
    PubMed     Abstract available

    February 2020
  8. BRUMINHENT J, Dajsakdipon T, Ingsathit A, Supaporn T, et al
    Impact of Cytomegalovirus Serostatus on Allograft Loss and Mortality Within the First Year After Kidney Transplantation: An Analysis of the National Transplant Registry.
    Transplant Proc. 2020 Feb 26. pii: S0041-1345(19)31677.
    PubMed     Abstract available

    December 2019
  9. ANDREANI M, Albano L, Benzaken S, Cassuto E, et al
    Monitoring of CMV-Specific Cell-Mediated Immunity in Kidney Transplant Recipients With a High Risk of CMV Disease (D+/R-): A Case Series.
    Transplant Proc. 2019 Dec 27. pii: S0041-1345(19)30314.
    PubMed     Abstract available

  10. APIWATTANAKUL N, Hongeng S, Anurathapan U, Pakakasama S, et al
    CMV-Reactive NK Cells in Pediatric Post-Hematopoietic Stem Cell Transplant.
    Transplant Proc. 2019 Dec 20. pii: S0041-1345(19)30946.
    PubMed     Abstract available

    November 2019
  11. MARRON RM, Vega Sanchez ME, Clauss H, Mamary AJ, et al
    Acute Hypoxemic Respiratory Failure and Native Lung Idiopathic Pulmonary Fibrosis Exacerbation in Single-lung Transplant Patients with Cytomegalovirus Disease: A Case Series.
    Transplant Proc. 2019 Nov 13. pii: S0041-1345(19)30516.
    PubMed     Abstract available

    August 2019
  12. LEE CH, Gwon JG, Jung CW
    Effectiveness of Thymoglobulin Induction Therapy in Kidney Transplant From Deceased Donor With Mild to Moderate Acute Kidney Injury.
    Transplant Proc. 2019 Aug 29. pii: S0041-1345(18)31857.
    PubMed     Abstract available

    July 2019
  13. USLU A, Ari A, Simsek C, Olgut AI, et al
    Evaluation of a Cytomegalovirus Prophylaxis Protocol in Cytomegalovirus-IgG Positive Renal Transplant Recipients (R+).
    Transplant Proc. 2019 Jul 26. pii: S0041-1345(18)31500.
    PubMed     Abstract available

  14. LEE JH, Kim HY, Lee DY, Kim YJ, et al
    Efficacy and Safety of Ultra-Low-Dose Valganciclovir Chemoprophylaxis for Cytomegalovirus Infection in High-Risk Kidney Transplantation Patients.
    Transplant Proc. 2019 Jul 24. pii: S0041-1345(19)30273.
    PubMed     Abstract available

    June 2019
  15. SINGH T, Peery S, Astor BC, Parajuli S, et al
    Cause of End-Stage Renal Disease Is Not a Risk Factor for Cytomegalovirus Infection After Kidney Transplant.
    Transplant Proc. 2019 Jun 27. pii: S0041-1345(18)31651.
    PubMed     Abstract available

    May 2019
  16. ALIYEVA N, Demir E, Akgul SU, Temurhan S, et al
    Effects of Rituximab on Atherosclerotic Biomarkers in Kidney Transplant Recipients.
    Transplant Proc. 2019;51:1118-1120.
    PubMed     Abstract available

    April 2019
  17. ITO K, Okuno T, Sawada A, Sakai K, et al
    Recurrent Aphthous Stomatitis Caused by Cytomegalovirus, Herpes Simplex Virus, and Candida Species in a Kidney Transplant Recipient: A Case Report.
    Transplant Proc. 2019;51:993-997.
    PubMed     Abstract available

    March 2019
  18. PENG H, Xiao J, Wan H, Shi J, et al
    Severe Gastric Mycormycosis Infection Followed by Cytomegalovirus Pneumonia in a Renal Transplant Recipient: A Case Report and Concise Review of the Literature.
    Transplant Proc. 2019;51:556-560.
    PubMed     Abstract available

    December 2018
  19. MAJEED A, Latif A, Kapoor V, Sohail A, et al
    Resistant Cytomegalovirus Infection in Solid-organ Transplantation: Single-center Experience, Literature Review of Risk Factors, and Proposed Preventive Strategies.
    Transplant Proc. 2018;50:3756-3762.
    PubMed     Abstract available

  20. CZARNECKA P, Czarnecka K, Tronina O, Durlik M, et al
    Cytomegalovirus Disease After Liver Transplant-A Description of a Treatment-Resistant Case: A Case Report and Literature Review.
    Transplant Proc. 2018;50:4015-4022.
    PubMed     Abstract available

  21. NAWASHIRO Y, Shiraki K, Yamamoto S, Takizawa K, et al
    Persistent Primary Cytomegalovirus Infection After Deceased Donor Kidney Transplant: Ganciclovir Susceptibility of Human Cytomegalovirus With UL97 D605E Mutation: A Case Report.
    Transplant Proc. 2018;50:3932-3936.
    PubMed     Abstract available

  22. SANDKOVSKY U, Qiu F, Kalil AC, Florescu A, et al
    Risk Factors for the Development of Cytomegalovirus Resistance in Solid Organ Transplantation: A Retrospective Case-Control Study.
    Transplant Proc. 2018;50:3763-3768.
    PubMed     Abstract available

  23. NUGROHO A, Lee KW, Kim H, Yi NJ, et al
    Challenging Alveolar Hemorrhage Complicating Pneumonia After Liver Transplantation: A Case Report.
    Transplant Proc. 2018;50:4046-4049.
    PubMed     Abstract available

    September 2018
  24. OSIAK M, Szubinska-Lelonkiewicz D, Wychowanski P, Karakulska-Prystupiuk E, et al
    Frequency of Pathologic Changes in the Oral Cavity in Patients Subjected to Long-term Pharmacologic Immunosuppressive Therapy After Kidney, Liver, and Hematopoietic Cell Transplantation.
    Transplant Proc. 2018;50:2176-2178.
    PubMed     Abstract available

    July 2018
  25. KOMOROWSKA-JAGIELSKA K, Heleniak Z, Debska-Slizien A
    Cytomegalovirus Status of Kidney Transplant Recipients and Cardiovascular Risk.
    Transplant Proc. 2018;50:1868-1873.
    PubMed     Abstract available

    June 2018
  26. HWANG SD, Lee JH, Lee SW, Kim JK, et al
    Effect of Low-Dose Vs Standard-Dose Valganciclovir in the Prevention of Cytomegalovirus Disease in Kidney Transplantation Recipients: A Systemic Review and Meta-Analysis.
    Transplant Proc. 2018 Jun 2. pii: S0041-1345(18)30067.
    PubMed     Abstract available

  27. BODRO M, Sanclemente G, Crespo G, Linares L, et al
    Severe Hepatitis C Recurrence as a Risk Factor for Opportunistic Infections in Liver Transplant Recipients.
    Transplant Proc. 2018;50:1437-1443.
    PubMed     Abstract available

  28. LEE H, Lee S, Jeon JS, Kwon SH, et al
    Thymoglobulin Versus Basiliximab Induction Therapy in Low-Risk Kidney Transplant Recipients: A Single-Center Experience.
    Transplant Proc. 2018;50:1285-1288.
    PubMed     Abstract available

    May 2018
  29. PARK WY, Kang SS, Jin K, Park SB, et al
    Is the Clinical Outcome Good or Bad in Patients Hospitalized Within 1 Year After Kidney Transplantation?
    Transplant Proc. 2018;50:1001-1004.
    PubMed     Abstract available

    April 2018
  30. LEE JH, Hwang SD, Song JH, Kim JH, et al
    Efficacy of Ultralow-Dose Valganciclovir Chemoprophylaxis for Cytomegalovirus Infection in ABO-Incompatible Kidney Transplantation Recipients.
    Transplant Proc. 2018 Apr 11. pii: S0041-1345(18)30575.
    PubMed     Abstract available

  31. NANMOKU K, Shinzato T, Kubo T, Shimizu T, et al
    Steroid Withdrawal Using Everolimus in ABO-Incompatible Kidney Transplant Recipients With Post-Transplant Diabetes Mellitus.
    Transplant Proc. 2018 Apr 6. pii: S0041-1345(18)30096.
    PubMed     Abstract available

  32. BOND MMK, Bond MMK, Sehn A, Dias VH, et al
    Cyclosporine Versus Tacrolimus: Which Calcineurin Inhibitor Has Influence on Cytomegalovirus Infection in Cardiac Transplantation?
    Transplant Proc. 2018;50:809-814.
    PubMed     Abstract available

    March 2018
  33. DE GRACIA-GUINDO MDC, Ruiz-Fuentes MDC, Galindo-Sacristan P, Osorio-Moratalla JM, et al
    Cytomegalovirus Infection Monitoring Based on Interferon Gamma Release Assay in Kidney Transplantation.
    Transplant Proc. 2018;50:578-580.
    PubMed     Abstract available

  34. CINTRA-CABRERA M, Suarez-Benjumea A, Bernal-Blanco G, Gonzalez-Roncero FM, et al
    Resistant Cytomegalovirus Infection After Renal Transplantation: Literature Review.
    Transplant Proc. 2018;50:575-577.
    PubMed     Abstract available

    January 2018
  35. BARADHI KM, Aure RL, El-Amm JM
    High-dose Valganciclovir Treatment for Resistant Cytomegalovirus Colitis due to UL97 and UL54 Mutations.
    Transplant Proc. 2018;50:142-144.
    PubMed     Abstract available

  36. NANMOKU K, Shinzato T, Kubo T, Shimizu T, et al
    Prevention of Late-Onset Cytomegalovirus Infection and Disease in Donor-Positive/Recipient-Negative Kidney Transplant Recipients Using Low-Dose Valganciclovir.
    Transplant Proc. 2018;50:124-129.
    PubMed     Abstract available

    December 2017
  37. HALLECK F, Khadzhynov D, Schrezenmeier E, Lehner L, et al
    Prolonged Low-Dose Prophylaxis With Valganciclovir in Cytomegalovirus-Negative Recipients of Kidney Transplants From Cytomegalovirus-Positive Donors Allows Seroconversion and Prevents Cytomegalovirus Disease.
    Transplant Proc. 2017;49:2280-2284.
    PubMed     Abstract available

    October 2017
  38. KAYA AH, Tekgunduz E, Akpinar S, Batgi H, et al
    Is Cytomegalovirus Surveillance Necessary for Patients With Low Reactivation Risk in an Autologous Hematopoietic Cell Transplantation Setting?
    Transplant Proc. 2017;49:1911-1915.
    PubMed     Abstract available

  39. FAVI E, Santangelo R, Iesari S, Morandi M, et al
    Enzyme-Linked Immunospot Assay as a Complementary Method to Assess and Monitor Cytomegalovirus Infection in Kidney Transplant Recipients on Pre-emptive Antiviral Therapy: A Single-Center Experience.
    Transplant Proc. 2017;49:1766-1772.
    PubMed     Abstract available

    September 2017
  40. ECHENIQUE IA, Beltran D, Ramirez-Ruiz L, Najafian N, et al
    Ganciclovir Dosing Strategies and Development of Cytomegalovirus Resistance in a Kidney Transplant Recipient: A Case Report.
    Transplant Proc. 2017;49:1560-1564.
    PubMed     Abstract available

    June 2017
  41. BRUMINHENT J, Rotjanapan P, Watcharananan SP
    Epidemiology and Outcome of Ganciclovir-Resistant Cytomegalovirus Infection After Solid Organ Transplantation: A Single Transplant Center Experience in Thailand.
    Transplant Proc. 2017;49:1048-1052.
    PubMed     Abstract available

  42. HARADA S, Nakamura T, Ushigome H, Akutsu N, et al
    Beneficial Effects of High-Dose Mizoribine on ABO-Incompatible Living-Related Kidney Transplantation: Two-Year Results by a Japanese Multicenter Study.
    Transplant Proc. 2017;49:967-970.
    PubMed     Abstract available

    May 2017
  43. BRASIL IRC, Custodio-Lima J, Sampaio RL, Pierre AMM, et al
    Pre-emptive Therapy for Cytomegalovirus in Post-transplantation Liver Patients With Donor-Positive/Recipient-Negative Serostatus.
    Transplant Proc. 2017;49:871-873.
    PubMed     Abstract available

  44. PRETAGOSTINI R, Poli L, Lai Q, Russo G, et al
    Pre-Emptive Therapy for the Treatment of Cytomegalovirus After Kidney Transplantation.
    Transplant Proc. 2017;49:638-641.
    PubMed     Abstract available

  45. PULITI REIGADA CH, de Ataide EC, de Almeida Prado Mattosinho T, Boin IFSF, et al
    Hepatic Artery Thrombosis After Liver Transplantation: Five-Year Experience at the State University of Campinas.
    Transplant Proc. 2017;49:867-870.
    PubMed     Abstract available

    April 2017
  46. KIR O, Zeytinoglu A, Arda B, Yilmaz M, et al
    Impact of Prophylaxis vs Pre-emptive Approach for Cytomegalovirus Infection in Kidney Transplant Recipients.
    Transplant Proc. 2017;49:537-540.
    PubMed     Abstract available

    March 2017
  47. RUAN V, Czer LS, Awad M, Kittleson M, et al
    Use of Anti-Thymocyte Globulin for Induction Therapy in Cardiac Transplantation: A Review.
    Transplant Proc. 2017;49:253-259.
    PubMed     Abstract available

    January 2017
  48. SHI Y, Liu H, Chen XG, Shen ZY, et al
    Comparison of Mizoribine and Mycophenolate Mofetil With a Tacrolimus-Based Immunosuppressive Regimen in Living-Donor Kidney Transplantation Recipients: A Retrospective Study in China.
    Transplant Proc. 2017;49:26-31.
    PubMed     Abstract available

    November 2016
  49. LUNA E, Caravaca F, Ferreira F, Fernandez N, et al
    Effect of Cytomegalovirus Infection on Survival of Older Kidney Transplant Patients (D+/R+): Impact of Valganciclovir Prophylaxis Versus Preemptive Therapy.
    Transplant Proc. 2016;48:2931-2937.
    PubMed     Abstract available

  50. CARBONE J, Gallego A, Fernandez Yanez J, Sousa I, et al
    Potential Immunomodulatory Role of Specific Anticytomegalovirus Intravenous Immunoglobulin in Heart Recipients.
    Transplant Proc. 2016;48:3027-3029.
    PubMed     Abstract available

    October 2016
  51. FENG S, Yang J, Wang W, Hu X, et al
    Incidence and Risk Factors for Cytomegalovirus Infection in Patients With Kidney Transplantation: A Single-Center Experience.
    Transplant Proc. 2016;48:2695-2699.
    PubMed     Abstract available

    May 2016
  52. MATSUURA R, Maeda A, Sakai R, Eguchi H, et al
    Human HLA-Ev (147) Expression in Transgenic Animals.
    Transplant Proc. 2016;48:1323-5.
    PubMed     Abstract available

    April 2016
  53. IWAMOTO H, Nakamura Y, Konno O, Tomita K, et al
    Immunosuppressive Therapy for Elderly Kidney Transplant Recipients.
    Transplant Proc. 2016;48:799-801.
    PubMed     Abstract available

  54. USHIGOME H, Uchida K, Nishimura K, Akioka K, et al
    Efficacy and Safety of High-Dose Mizoribine Combined With Cyclosporine, Basiliximab, and Corticosteroids in Renal Transplantation: A Japanese Multicenter Study.
    Transplant Proc. 2016;48:794-8.
    PubMed     Abstract available

    March 2016
  55. ARZE S, Arze L, Abecia C
    Post-transplantation Infections in Bolivia.
    Transplant Proc. 2016;48:646-53.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Cytomegalovirus Infection is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.